Trial Profile
A Dose Response Study of CTS-1027 in Hepatitis C Patients
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs CTS 1027 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors Conatus Pharmaceuticals
- 18 Apr 2010 Results presented at the 45th Annual Meeting of the European Association for the Study of the Liver.
- 22 Jan 2010 Actual end date (July 2009) added as reported by ClinicalTrials.gov.
- 22 Jan 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.